The Combination of Rituximab, Plasmapheresis, Intravenous Immunoglobulins and Pre-Transplant Immunosuppression Is an Effective Desensitization Strategy for Patients with Sickle Cell Disease and High Donor Specific Anti-Human Leukocyte Antigen Titer Undergoing Haploidentical Bone Marrow Transplant

Eden Biltibo(Vanderbilt University Medical Center), Josu de la Fuente(Imperial College Healthcare NHS Trust), Lindsay Orton(Vanderbilt University), Leena Karnik, Reena Jayani(Vanderbilt University Medical Center), Adam Gassas, Adetola A. Kassim(Vanderbilt University), James A. Connelly(Michigan Center for Translational Pathology), Brian G. Engelhardt(Vanderbilt University Medical Center), Bhagirathbhai Dholaria(Vanderbilt University Medical Center), Carrie L. Kitko(Vanderbilt University Medical Center), Farah O’Boyle, Katie S. Gatwood(Vanderbilt University Medical Center), Salyka Sengsayadeth(VA Tennessee Valley Healthcare System), Bipin N. Savani(Vanderbilt University Medical Center), Karina Wilkerson(Vanderbilt University Medical Center)
Transplantation and Cellular Therapy
February 1, 2023
Cited by 0


Related Papers